Risk of Circulating Tumor Cells and Clinical Blood Transfusion

WANG Haiying; ZHANG Jinjin; SUN Xiaoli; XING Yanchao

doi:10.12290/xhyxzz.2024-0493

Turn off MathJax

Article Contents

Abstract

References

WANG Haiying, ZHANG Jinjin, SUN Xiaoli, XING Yanchao. Risk of Circulating Tumor Cells and Clinical Blood Transfusion[J]. Medical Journal of Peking Union Medical College Hospital. DOI: 10.12290/xhyxzz.2024-0493

Citation:

PDF (904 KB)

Risk of Circulating Tumor Cells and Clinical Blood Transfusion

Department of Blood Transfusion, Xinjiang Military General Hospital, Urumqi 830002, China

More Information

Received Date: July 02, 2024
Accepted Date: January 12, 2025
Available Online: January 21, 2025

Graphical Abstract

Abstract

Abstract

Circulating tumor cells (CTCs) have the ability to sow tumors and can be found in the peripheral blood of patients with precancerous lesions and healthy people. However, CTCs are not currently screened in the donors blood. A large number of allogeneic blood transfusions occurred worldwide each year, and allogeneic blood transfusions expose recipients to the risk of transmission and affect tumors associated with donor CTCs. Although leukocyte filtration can not completely remove tumor cells in the blood, it can effectively reduce the number of white blood cells in the blood and reduce their proliferation ability. Blood irradiation can effectively destroy the DNA of CTCs in the blood, and inhibit the occurrence and metastasis of tumors caused by the infusion of allogeneic blood containing CTCs. Therefore, we should pay attention to the potential risk of CTCs on clinical transfusion, and strengthen the preclinical treatment of blood to avoid donor-related tumor infection in blood recipients due to clinical transfusion.
- CTCs,
- allogeneic blood transfusions,
- tumor metastasis,
- blood irradiation,
- leukoreduction

FullText(HTML)

References (71)

References

[1]	Bray F, Laversanne M, Sung H, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin,2024,74(3):229-263.
[2]	Ashworth T R.A case of cancer in which cells similar to those in the tumors were seen in the blood after death[J]. Med J Aust, 1869,14:146-147
[3]	Fan T, Kuang G, Long R,et al. The overall process of metastasis: From initiation to a new tumor[J]. Biochim Biophys Acta Rev Cancer, 2022,1877(4):188750.
[4]	Fabisiewicz A, Grzybowska E. CTC clusters in cancer progression and metastasis[J]. Med Oncol,2017,34(1):12.
[5]	Vardas V, Politaki E, Pantazaka E, et al. Epithelial-to-mesenchymal transition of tumor cells: cancer progression and metastasis[J]. Int JDev Biol,2022,66(1-2-3):277-283.
[6]	Serrano MJ, Rolfo C, Expósito-Hernandez J,et al. Circulating tumor cells in cancer-risk populations as a cancer interception tool[J].Int Rev Cell Mol Biol,2023,381:113-129.
[7]	Mamdouhi T, Twomey JD, McSweeney KM,et al. Fugitives on the run: circulating tumor cells (CTCs) in metastatic diseases[J]. Cancer Metastasis Rev,2019,38(1-2):297-305.
[8]	Marrugo-Ramírez J, Mir M, Samitier J.Blood-based cancer biomarkers in liquid biopsy:a promising non-invasive alternative to tissue biopsy[J]. Int J Mol Sci, 2018,19(10):2877.
[9]	Zheng S, Girgis MD, Tomlinson JS. Circulating tumor cells: metastases caught in the act[J]. Ann Surg., 2023,277(6):873-876.
[10]	Lin D, Shen L, Luo M, et al. Circulating tumor cells: biology and clinical significance[J].Signal Transduct Target Ther,2021,6(1):404.
[11]	Kojima M, Hiyama E. Circulating tumor cells and tumor progression, metastasis, and poor prognosis in patients with neuroblastoma[J]. Anticancer Res,2023,43(10):4327-4331.
[12]	Castro-Giner F, Aceto N. Tracking cancer progression: from circulating tumor cells to metastasis[J].Genome Med,2020,12(1):31.
[13]	Jiang M, Jin S, Han J, et al. Detection and clinical significance of circulating tumor cells in colorectal cancer[J]. Biomak Res,2021,9(1):85.
[14]	Feng Z, Wu J, Lu Y, et al. Circulating tumor cells in the early detection of human cancers[J].Int J Biol Sci,2022,18(8):3251-3265.
[15]	Su Z, Zhao J, Ke S, et al. Clinical significance of circulating tumor cells via combined whole exome sequencing in early stage cancer screening: a case report[J].Exp Ther Med,2018,16(3):2527-2533. [ 16] Reiter JG, Makohon-Moore AP, Gerold JM, et al. Reconstructing metastatic seeding patterns of human cancers[J].Nat Commun,2017,8:14114.
[17]	[ 19] Zanella S, Garani MC, Borgna-Pignatti C. Malignancies and thalassemia: a review of the literature[J]. Ann N Y Acad Sci,2016,1368(1):140-8.
[20]	Yang TO, Cairns BJ, Reeves GK, et al. Cancer risk among 21st century blood transfusion recipients[J].Ann Oncol,2017,28(2):393-399.
[21]	Zheng S, Girgis MD, Tomlinson JS. Circulating tumor cells: metastases caught in the act[J]. Ann Surg,2023,277(6):873-876. [ 22] Stammnitz MR, Gori K, Kwon YM, et al. The evolution of two transmissible cancers in Tasmanian devils[J]. Science,2023,380(6642):283-293.
[23]	Bramwell G, DeGregori J, Thomas F, et al. Transmissible cancers, the genomes that don't melt down[J]. Evolution,2024:qpae063. doi: 10.1093/evolut/qpae063. Epub ahead of print. PMID: 38656785.
[24]	Pearse AM, Swift K. Allograft theory: transmission of devil facial-tumour disease[J]. Nature. 2006,439(7076):549.
[25]	Raven N, Klaassen M, Madsen T, et al. Complex associations between cancer progression and immune gene expression reveals early influence of transmissible cancer on tasmanian devils[J]. Front Immunol, 2024,15:1286352. doi: 10.3389/fimmu.2024.1286352. PMID: 38515744; PMCID: PMC10954821.
[26]	Hussey K, Caldwell A, Kreiss A, et al. Expression of the nonclassical MHC Class I, saha-UD in the transmissible cancer devil facial tumour disease (DFTD)[J]. Pathogens 2022,11(3):351.
[27]	Petrohilos C, Patchett A, Hogg CJ, et al. Tasmanian devil cathelicidins exhibit anticancer activity against devil facial tumour disease (DFTD) cells[J]. Sci Rep,2023,13(1):12698.
[28]	Rebbeck CA, Thomas R, Breen M, et al. Origins and evolution of a transmissible cancer[J]. Evolution,2009,63(9):2340-2349.
[29]	Faro TAS, de Oliveira EHC. Canine transmissible venereal tumor - from general to molecular characteristics: A review[J]. Anim Genet. 2023,54(1):82-89.
[30]	Giersch RM, Hart SFM, Reddy SG, et al. Survival and detection of bivalve transmissible neoplasia from the soft-shell clam mya arenaria(MarBTN) in seawater[J]. Pathogens. 2022 Feb 23;11(3):283. [ 31] Silva RCMC, Panis C, Pires BRB. Lessons from transmissible cancers for immunotherapy and transplant[J]. Immunol Med,2022,45(3):146-161.
[32]	Arakawa A, Tao K, Kohno T, et al. Cross-individual cancer transmission to children during the gestational and perinatal periods[J]. Cancer Sci,2024,115(4):1039-1047.
[33]	Pye RJ, Pemberton D, Tovar C, et al. A second transmissible cancer in tasmanian devils[J]. Proc Natl Acad Sci U S A, 2016,113(2):374-379.
[34]	Scanlon EF, Hawkins RA, Fox WW,et al. Fatal homotransplanted melanoma[J]. Cancer,1965(18):782-9.
[35]	Greaves M, Hughes W. Cancer cell transmission via the placenta[J]. Evol Med Public Health,2018,2018(1):106-115.
[36]	Arakawa A, Ichikawa H, Kubo T, et al. Vaginal transmission of cancer from mothers with cervical cancer to infants[J]. N Engl J Med,2021,384(1):42-50.
[37]	Khazzaka A, Rassy E, Sleiman Z, et al. Systematic review of fetal and placental metastases among pregnant patients with cancer[J]. Cancer Treat Rev.,2022,104:102356. doi: 10.1016/j.ctrv.2022.102356. Epub 2022 Feb 11. PMID: 35182890.
[38]	Glanc P. Fetal and placental metastases associated with maternal cancers[J]. Abdom Radiol (NY),2023,48(5):1784-1792.[ 39] Desai R, Collett D, Watson CJ, et al. Cancer transmission from organ donors-unavoidable but low risk[J]. Transplantation,2012,94(12):1200-7.
[40]	Gingras MC, Sabo A, Cardenas M, et al. Sequencing of a central nervous system tumor demonstrates cancer transmission in an organ transplant[J]. Life Sci Alliance,2021,4(9):e202000941. doi: 10.26508/lsa.202000941. PMID: 34301805; PMCID: PMC8321656.
[41]	Greenhall GHB, Ibrahim M, Dutta U, et al. Donor-transmitted cancer in orthotopic solid organ transplant recipients: a systematic review[J]. Transpl Int,2022,35:10092.
[42]	Cooper JM, Samueli B, Mazor E,et al. Molecularly confirmed female donor-transmitted lobular breast cancer to male following renal transplantation[J]. pathobiology,2023,90(1):63-68.
[43]	Malvi D, Vasuri F, Albertini E, et al. Donors risk assessment in transplantation: From the guidelines to their real-world application[J]. Pathol Res Pract,2024,255:155210. doi: 10.1016/j.prp.2024.155210. Epub 2024 Feb 12. PMID: 38422913. [ 44] Molodysky E, Grant R. Person-to-person cancer transmission via allogenic blood transfusion[J].Asian Pac J Cancer Prev, 2021,22(3):641-649.
[45]	Hamza B, Miller AB, Meier L, et al. Measuring kinetics and metastatic propensity of CTCs by blood exchange between mice[J].Nat Commun,2021,12(1):5680.
[46]	Salu P, Reindl KM. Advancements in circulating tumor cell research: bridging biology and clinical applications[J]. Cancers (Basel), 2024,16(6):1213. [ 47] Micalizzi DS, Maheswaran S, Haber DA. A conduit to metastasis: circulating tumor cell biology[J]. Genes Dev,2017,31(18):1827-1840.
[48]	Zhang J, Chen S, Yan Y, et al. Extracellular ubiquitin is the causal link between stored blood transfusion therapy and tumor progression in a melanoma mouse model[J]. J Cancer,2019,10(12):2822-2835.
[49]	Yachida S, Jones S, Bozic I, et al. Distant metastasis occurs late during the genetic evolution of pancreatic cancer[J].Nature,2010, 467(7319):1114-7.
[50]	Das S, Dey MK, Devireddy R, et al. Biomarkers in cancer detection, diagnosis, and prognosis[J]. Sensors (Basel),2023,24(1):37.
[51]	Vidlarova M, Rehulkova A, Stejskal P, et al. Recent advances in methods for circulating tumor cell detection[J]. Int J Mol Sci,2023,24(4):3902.
[52]	Brenner DR, Gillis J, Demers AA, et al. Projected estimates of cancer in Canada in 2024[J]. CMAJ,2024,196(18):E615-E623.
[53]	Gammon RR, Hopkins C, Mathur G,et al. The science…or not behind deferrals of blood donors with a history of cancer[J]. Transfusion,2023,3(8):1538-1545.
[54]	Passaro A, Al Bakir M, Hamilton EG,et al. Cancer biomarkers: Emerging trends and clinical implications for personalized treatment[J]. Cell,2024,187(7):1617-1635.
[55]	Vora N, Shekar P, Hanulia T, et al. Deep learning-enabled detection of rare circulating tumor cell clusters in whole blood using label-free, flow cytometry[J]. Lab Chip,2024,24(8):2237-2252.
[56]	Bandini S, Ulivi P, Rossi T. Extracellular vesicles, circulating tumor cells, and immune checkpoint inhibitors: hints and promises[J]. Cells,2024,13(4):337.
[57]	Chen P, Zhang L, Cao X,et al. Detection of circulating plasma cells in peripheral blood using deep learning-based morphological analysis[J]. Cancer,2024,130(10):1884-1893.
[58]	Malkawi W, Lutfi A, Afghan MK, et al. Circulating tumour cell enumeration, biomarker analyses, and kinetics in patients with colorectal cancer and other GI malignancies[J]. Front Oncol,2023(13):1305181.
[59]	Liu X, Zhang Y, Li X, et al. Raman spectroscopy combined with malaria protein for early capture and recognition of broad-spectrumcirculating tumor cells[J]. Int J Mol Sci,2023,24(15):12072.
[60]	Vora N, Shekar P, Hanulia T, et al. Deep learning-enabled detection of rare circulating tumor cell clusters in whole blood using label-free, flow cytometry[J]. Lab Chip,2024,24(8):2237-2252.
[61]	Pedrosa VA, Chen K, George TJ, et al. Gold nanoparticle-based microfluidic chips for capture and detection of circulating tumor cells[J]. Biosensors (Basel),2023,13(7):706.
[62]	Yu N, Ma G, Chen Y, et al. MnO2 nanosheets and gold nanoparticles supported electrochemical detection of circulating tumor cells[J]. Colloids Surf B Biointerfaces,2023(229):113482.
[63]	Chen Y, Lin M, Ye D, et al. Functionalized tetrahedral DNA frameworks for the capture of circulating tumor cells[J].Nat Protoc,2024,19(4):985-1014.
[64]	Xing L, Wan X, Yu MT, et al. A novel whole blood purifier for efficient capture and separation of circulating tumor cells[J]. Biosens Bioelectron,2023(232):115292.
[65]	Wan C, Zhou B. Research progress on circulating tumor cells of hepatocellular carcinoma[J].J Interv Med,2021,4(4):181-183.
[66]	Elmakki EE, Madkhali MA, Oraibi O, et al. Transfusion-associated graft-versus-host disease in adults[J].Cureus,2023,15(8):e44148.
[67]	Frühauf NR, Dumpich O, Kaudel CP, et al. Filtration of malignant cells: tumour cell depletion in an ex vivo model using a leukocyte adhesion filter[J].Perfusion,2001,16:51-5.
[68]	尚玉,邵小宝,周琳,等.白细胞滤器去除血液肿瘤细胞的实验研究[J].中国输血杂志,2021,34(05):452-455.
[69]	Chun S, Phan MT, Hong S, et al. Double-filtered leukoreduction as a method for risk reduction of transfusion-associated graft-versus-host disease[J]. PLoS One,2020,15(3):e0229724.
[70]	Mykhailova O, Turner TR, Olafson C, et al. Hypothermic storage of leukoreduced red blood cells for greater than 21 days is a safe alternative to irradiation[J]. Transfusion,2021,61(4):1247-1257.
[71]	Rodriguez JV, Tormey CA. Can transfusion-associated graft-versus-host disease (TA-GvHD) be prevented with leukoreduction alone[J] ? Transfus Apher Sci,2022,61(2):103402.
[72]	Grana NH, Kao KJ. Use of 8-methoxypsoralen and ultraviolet-A pretreated platelet concentrates to prevent alloimmunization against class I major histocompatibility antigens[J]. Blood,199,77(11):2530-7.
[73]	Poli MC, Villa LL, Colella R,et al. Molecular evidence of tumour cell removal from salvaged blood after irradiation and leucocyte depletion[J]. Transfus Med,2004,14(2):151-5.
[74]	Uchida S, Tadokoro K, Takahashi M,et al. Analysis of 66 patients definitive with transfusion-associated graft-versus-host disease and the effect of universal irradiation of blood[J]. Transfus Med,2013,23(6):416-22.
[75]	Arjunan C, Khetan D, Singh V,et al. Demographics and appropriateness of cellular blood component irradiation practices: Ambispective analysis from a tertiary care center[J]. Transfus Apher Sci,2023,62(3):103651.
[76]	曹庆盛,王明慧.辐照血液在血液学方面的临床应用[J].中国实验血液学杂志,2019,27(06):2030-2034.
[77]	Adane T, Enawgaw B. Human leukocyte antigen alloimmunization prevention mechanisms in blood transfusion[J]. Asian J Transfus Sci,2023,17(2):264-272.
[78]	Kim S, Jo KW, Park JM,et al. Irradiation is not sufficient to eradicate residual immortalized erythroid cells in in vitro-generated red blood cell products[J]. Transfusion, 2023,63(6):1122-1128.
[79]	Li M, Irsch J, Corash L, Benjamin RJ. Is pathogen reduction an acceptable alternative to irradiation for risk mitigation of transfusion-associated graft versus host disease[J] ? Transfus Apher Sci,2022,61(2):103404.

[1]	YAN Xinchun, HUO Li. Evaluation of Von Hippel-Lindau Syndrome Through Novel Small Molecular Tracer ⁶⁸Ga-NY104 PET/CT Imaging[J]. Medical Journal of Peking Union Medical College Hospital, 2024, 15(4): 911-915. DOI: 10.12290/xhyxzz.2024-0216
[2]	LIU Wei, XU Xiaohan, YU Xuerong. Association Between Preoperative Hypoalbuminemia and Risk of Perioperative Allogeneic Red Blood Cell in Patients Undergoing Cytoreductive Surgery for Ovarian Cancer: A Single-center Retrospective Cohort Study[J]. Medical Journal of Peking Union Medical College Hospital, 2024, 15(4): 839-844. DOI: 10.12290/xhyxzz.2023-0544
[3]	ZHANG Lu, LI Jian. Castleman Disease in China: State-of-the-art Technology Before the Era of IL-6 Targeted Therapy[J]. Medical Journal of Peking Union Medical College Hospital, 2023, 14(5): 911-914. DOI: 10.12290/xhyxzz.2023-0227
[4]	SHEN Jing, LIU Zhikai, GUAN Hui, ZHEN Hongnan, SUN Xiansong, JIANG Fei, ZHANG Yue, YU Lang, ZHANG Jie, ZHANG Fuquan. Total Marrow and Lymphoid Irradiation: A New Technology Assisting in Myeloablating Before Hematopoietic Stem Cell Transplantation[J]. Medical Journal of Peking Union Medical College Hospital, 2023, 14(4): 895-899. DOI: 10.12290/xhyxzz.2022-0503
[5]	XIAO Nan, LI Zhanfeng, YAO Jianxin, PAN Zhiyao, YAO Zhifeng. Long Non-coding RNA and Cancer Stem Cells[J]. Medical Journal of Peking Union Medical College Hospital, 2021, 12(3): 373-379. DOI: 10.12290/xhyxzz.20190231
[6]	Teng ZHU, Hong-zhong JIN. mRNA Expression of Methylase and Methyl-CpG Binding Protein in Peripheral Blood Mononuclear Cells from Patients with Generalized Pustular Psoriasis[J]. Medical Journal of Peking Union Medical College Hospital, 2019, 10(4): 358-363. DOI: 10.3969/j.issn.1674-9081.2019.04.009
[7]	Jia-qi ZHANG, Lei LIU, Gui-ge WANG, Wen-liang BAI, Shan-qing LI. Clinical Pathological Features and Prognosis of Non-small Cell Lung Cancer with Skip N2 Lymph Node Metastasis[J]. Medical Journal of Peking Union Medical College Hospital, 2019, 10(3): 272-277. DOI: 10.3969/j.issn.1674-9081.2019.03.015
[8]	Si-yi CAI, Jian-xiong SHEN, Xi-sheng WENG, Bao-zhong ZHANG, Bo YANG, Bin FENG, Gui-xing QIU. Effect of Comprehensive and Whole Process Blood Management on Allogeneic Transfusion in Orthopedic Surgical Patients[J]. Medical Journal of Peking Union Medical College Hospital, 2015, 6(4): 286-290. DOI: 10.3969/j.issn.1674-9081.2015.04.011
[9]	Ming-yang LIU, Jie CHEN, Jian GUAN. Local Injections of Cholesterol-conjugated let-7a Mimics Inhibit Tumor Growth and Metastasis of Hepatocellular Carcinoma in a Subcutaneous Xenograft Nude Mouse Model by Targeting K-Ras, H-Ras, and N-Ras[J]. Medical Journal of Peking Union Medical College Hospital, 2015, 6(2): 133-139. DOI: 10.3969/j.issn.1674-9081.2015.02.012
[10]	Jun LI, Lin-na WANG, He-yi ZHENG. Levels of Interleukin-2 in Peripheral Blood of Patients with Secondary Syphilis[J]. Medical Journal of Peking Union Medical College Hospital, 2012, 3(4): 395-397. DOI: 10.3969/j.issn.1674-9081.2012.04.007

Cited By

Get Citation

PDF

XML

Article Metrics

Article views (44) PDF downloads (0)

Address：	Room 302,Third Floor,Building 7, No. 1 Shuaifuyuan, Wangfujing, Dongcheng District, Beijing 100730, China
Tel：	010-69154261/4262
E - mail：	medj@pumch.cn mjpumch@126.com
Copyright of website：	Editorial Office of Medical Journal of Peking Union Medical College Hospital

Risk of Circulating Tumor Cells and Clinical Blood Transfusion

Abstract

References

Related Articles

Catalog

Article Metrics

Related

Risk of Circulating Tumor Cells and Clinical Blood Transfusion

Abstract

References

Related Articles

Catalog

Article Metrics

Related

Export File

Citation

Format

Content